Luc Dirix

13.2k total citations · 2 hit papers
105 papers, 6.4k citations indexed

About

Luc Dirix is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Luc Dirix has authored 105 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Molecular Biology, 55 papers in Oncology and 31 papers in Cancer Research. Recurrent topics in Luc Dirix's work include Angiogenesis and VEGF in Cancer (25 papers), Hedgehog Signaling Pathway Studies (19 papers) and Estrogen and related hormone effects (13 papers). Luc Dirix is often cited by papers focused on Angiogenesis and VEGF in Cancer (25 papers), Hedgehog Signaling Pathway Studies (19 papers) and Estrogen and related hormone effects (13 papers). Luc Dirix collaborates with scholars based in Belgium, United States and Germany. Luc Dirix's co-authors include Peter Vermeulen, Ina Benoy, Adrian L. Harris, Michael R. Migden, Stephen B. Fox, Peter A. van Dam, Anne Lynn S. Chang, Noel Weidner, Giampietro Gasparini and Karl D. Lewis and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Luc Dirix

103 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. profile →
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

1996 631 citations Peter Vermeulen, Giampietro Gasparini et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luc Dirix Belgium	38	3.8k	2.8k	1.8k	1.1k	1.1k	105	6.4k
Lori A. Erickson United States	40	1.5k 0.4×	2.3k 0.8×	673 0.4×	587 0.5×	992 0.9×	185	5.5k
Robert R. McWilliams United States	46	2.4k 0.6×	5.9k 2.1×	1.9k 1.0×	1.9k 1.7×	1.1k 1.0×	206	8.4k
Futoshi Akiyama Japan	41	1.7k 0.4×	2.5k 0.9×	2.7k 1.5×	635 0.6×	255 0.2×	251	6.1k
Roland Penzel Germany	40	1.7k 0.4×	1.8k 0.6×	1.3k 0.7×	1.5k 1.4×	459 0.4×	134	4.4k
Raoul Tibes United States	34	3.6k 1.0×	1.5k 0.5×	576 0.3×	418 0.4×	488 0.5×	144	5.3k
Samuel E. DePrimo United States	28	2.7k 0.7×	2.2k 0.8×	1.3k 0.7×	2.5k 2.2×	361 0.3×	40	5.3k
Kyriakos P. Papadopoulos United States	47	4.3k 1.1×	3.8k 1.3×	1.2k 0.7×	1.5k 1.3×	409 0.4×	324	8.1k
Laurent Arnould France	38	1.4k 0.4×	2.8k 1.0×	1.4k 0.7×	651 0.6×	290 0.3×	172	5.3k
Lukas C. Heukamp Germany	44	3.4k 0.9×	1.9k 0.7×	1.5k 0.8×	1.7k 1.5×	358 0.3×	175	6.1k
Yun Gong United States	35	1.1k 0.3×	1.9k 0.7×	1.1k 0.6×	1.0k 0.9×	307 0.3×	118	3.6k

Countries citing papers authored by Luc Dirix

Since Specialization

Citations

This map shows the geographic impact of Luc Dirix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Dirix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Dirix more than expected).

Fields of papers citing papers by Luc Dirix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Dirix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Dirix. The network helps show where Luc Dirix may publish in the future.

Co-authorship network of co-authors of Luc Dirix

This figure shows the co-authorship network connecting the top 25 collaborators of Luc Dirix. A scholar is included among the top collaborators of Luc Dirix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luc Dirix. Luc Dirix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baelen, Karen Van, François Richard, Maria Margarete Karsten, et al.. (2025). Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. Breast Cancer Research. 27(1). 106–106. 1 indexed citations

Bartlett, John M.S., Keying Xu, Gregory R. Pond, et al.. (2024). Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial. Clinical Cancer Research. 30(8). 1509–1517. 2 indexed citations

Wildiers, Hans, Anne Armstrong, Eveline Cuypere, et al.. (2023). Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clinical Cancer Research. 30(3). 532–541. 12 indexed citations

Barnhill, Raymond L., Claire Lugassy, Cornelis Verhoef, et al.. (2019). Pathological features of vessel co-option versus sprouting angiogenesis. Angiogenesis. 23(1). 43–54. 49 indexed citations

Lear, John T., Michael R. Migden, Karl D. Lewis, et al.. (2017). Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology. 32(3). 372–381. 137 indexed citations

Migden, Michael R., Anne Lynn S. Chang, Luc Dirix, Alexander Stratigos, & John T. Lear. (2017). Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews. 64. 1–10. 65 indexed citations

Sekulić, Aleksandar, Michael R. Migden, Karl D. Lewis, et al.. (2015). Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. Journal of the American Academy of Dermatology. 72(6). 1021–1026.e8. 154 indexed citations

Sharpe, Hayley J., Grégoire Pau, Gerrit J.P. Dijkgraaf, et al.. (2015). Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma. Cancer Cell. 27(3). 327–341. 296 indexed citations

Jansen, Maurice P.H.M., Theo Knijnenburg, Iris Simón, et al.. (2013). Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer. Cancer Research. 73(22). 6632–6641. 57 indexed citations

10.

Helmijr, Jean, Maxime P. Look, Irene Lurkin, et al.. (2013). Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Research and Treatment. 139(1). 39–49. 43 indexed citations

11.

Laere, Steven Van, et al.. (2012). Regulation of Inflammatory Breast Cancer Cell Invasion through Akt1/PKBα Phosphorylation of RhoC GTPase. Molecular Cancer Research. 10(10). 1306–1318. 48 indexed citations

12.

Trinh, Xuan Bich, Peter A. van Dam, Peter Vermeulen, et al.. (2011). VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clinical & Translational Oncology. 13(11). 805–808. 4 indexed citations

13.

Vermeulen, Peter, Luc Van Kaer, & Luc Dirix. (2010). Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer. Cancer. 116(S11). 2748–2754. 72 indexed citations

14.

Auwera, Ilse Van der, Dieter Peeters, Ina Benoy, et al.. (2009). Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer. British Journal of Cancer. 102(2). 276–284. 145 indexed citations

15.

Benoy, Ina, Hilde Elst, Peter A. van Dam, et al.. (2006). Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clinical Chemistry and Laboratory Medicine (CCLM). 44(9). 25 indexed citations

16.

Salgado, Roberto, Ina Benoy, Reinhilde Weytjens, et al.. (2002). Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. British Journal of Cancer. 87(12). 1437–1444. 52 indexed citations

17.

Vermeulen, P, Giampietro Gasparini, Stephen B. Fox, et al.. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. European Journal of Cancer. 38(12). 1564–1579. 385 indexed citations

18.

Lauwers, Patrick, Guy Hubens, Jeroen Hendriks, et al.. (1999). Effects of Suramin on Anastomotic Colon Tumors in a Rat Model. European Surgical Research. 31(4). 347–356. 2 indexed citations

19.

Dirix, Luc, Peter Vermeulen, Guy Hubens, et al.. (1996). Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Annals of Oncology. 7(8). 843–848. 116 indexed citations

20.

Dirix, Luc & Allan T. van Oosterom. (1995). Diagnosis and treatment of soft tissue sarcomas in adults. Current Opinion in Oncology. 7(4). 340–348. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact